Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) EBITDA: 2016-2024

Historic EBITDA for Protagonist Therapeutics (PTGX) over the last 9 years, with Dec 2024 value amounting to $252.8 million.

  • Protagonist Therapeutics' EBITDA fell 11.98% to -$46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 87.25%. This contributed to the annual value of $252.8 million for FY2024, which is 369.98% up from last year.
  • As of FY2024, Protagonist Therapeutics' EBITDA stood at $252.8 million, which was up 369.98% from -$93.7 million recorded in FY2023.
  • Protagonist Therapeutics' EBITDA's 5-year high stood at $252.8 million during FY2024, with a 5-year trough of -$131.4 million in FY2022.
  • In the last 3 years, Protagonist Therapeutics' EBITDA had a median value of -$93.7 million in 2023 and averaged $9.3 million.
  • Per our database at Business Quant, Protagonist Therapeutics' EBITDA slumped by 95.06% in 2021 and then surged by 369.98% in 2024.
  • Protagonist Therapeutics' EBITDA (Yearly) stood at -$64.5 million in 2020, then plummeted by 95.06% to -$125.8 million in 2021, then dropped by 4.39% to -$131.4 million in 2022, then rose by 28.71% to -$93.7 million in 2023, then surged by 369.98% to $252.8 million in 2024.